Close this search box.

Sensus Healthcare, Inc. Receives the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award

September 7, 2016
– Sensus Credited with Advancing Superficial Radio Therapy as Viable Treatment Option for NMSC –

BOCA RATON, Fla., Sept. 7, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions such as keloids with superficial radiation therapy (SRT), announced today it has been named the winner of the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award for its innovative therapy treatment technology. Sensus Healthcare scored an average 9.5 out of 10 possible points on the Frost & Sullivan Technology Leadership Scorecard across 10 different criteria assessing technology leverage and business impact.

“We are grateful to Frost & Sullivan for recognizing our SRT technology for a second time. In 2014, we were awarded the Frost & Sullivan New Product Innovation Leadership Award for Non-melanoma Skin Cancer Therapy, and now we are being recognized for our technology leadership,” said Joseph Sardano, President and CEO of Sensus Healthcare. “This award highlights the transformation Sensus has undergone in recent years as well as the acceptance we have achieved with physicians and patients. The Frost & Sullivan award not only validates our technology, but supports our efforts to increase the awareness of our unique technology solution to effectively address an important niche of the cancer treatment market.”

Each year, Frost & Sullivan recognizes companies that lead the development and successful introduction of high-tech solutions that address customers’ most pressing needs and alter the industry or business landscape in the process. After a careful review of the NMSC industry, Bhargav Rajan, Frost & Sullivan Healthcare analyst, noted that “advances in diagnoses, increasing awareness, and the nature of the disease itself have made the management of NMSC ripe for overhaul.”

“There is an urgent market need for a patient-friendly, clinically-effective, and aesthetically-appealing option for the treatment of NMSC,” Rajan continued. “We believe Sensus’ SRT devices best the competition in radiation therapy and surgery by providing a scar-free, aesthetically-appealing, and clinically-effective therapy. Sensus deserves credit for bringing back superficial radiation therapy as a viable option and, in some cases, offering the only option for treating skin cancers and dermatological conditions.”

Sensus Healthcare was launched with the goal to develop and market advanced medical devices that would allow the company to achieve 2 goals: address large and underserved market opportunities within the medical device arena and offer a disruptive and compelling value proposition to physicians and patients alike. The company’s SRT therapy treatment devices achieve both. SRT is virtually painless; does not require anesthesia, cutting, or stitching; does not result in bleeding or scarring; and is cost effective.

About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices: SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from 31 offices on 6 continents. To join Frost & Sullivan’s Growth Partnership, please visit

Frost & Sullivan Awards follow a 10-step process to evaluate award candidates and assess their fit with select best practice criteria. The reputation and integrity of the awards are based on close adherence to this process. The firm’s 360-degree research methodology represents the analytical rigor of its research process, offering a 360-degree-view of industry challenges, trends, and issues by integrating all 7 of Frost & Sullivan’s research methodologies into an evaluation platform for benchmarking industry participants and for identifying those performing at best-in-class levels.

Investor Relations:
Jeffrey Goldberger / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1267
Email: [email protected] / [email protected]

To view the original version on PR Newswire, visit:–sullivan-2016-global-non-melanoma-skin-cancer-therapy-technology-leadership-award-300323425.html

SOURCE Sensus Healthcare, Inc.